Fate Therapeutics Current Ratio 2012-2021 | FATE

Current and historical current ratio for Fate Therapeutics (FATE) from 2012 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Fate Therapeutics current ratio for the three months ending June 30, 2021 was 6.75.
Fate Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.71B $0.11B 6.75
2021-03-31 $0.80B $0.10B 8.50
2020-12-31 $0.49B $0.09B 5.78
2020-09-30 $0.50B $0.05B 9.17
2020-06-30 $0.54B $0.05B 11.92
2020-03-31 $0.21B $0.03B 8.36
2019-12-31 $0.23B $0.03B 8.17
2019-09-30 $0.31B $0.04B 7.53
2019-06-30 $0.17B $0.03B 5.62
2019-03-31 $0.19B $0.03B 6.40
2018-12-31 $0.21B $0.03B 7.53
2018-09-30 $0.21B $0.02B 9.44
2018-06-30 $0.08B $0.02B 4.92
2018-03-31 $0.09B $0.01B 7.20
2017-12-31 $0.10B $0.01B 9.29
2017-09-30 $0.07B $0.01B 7.21
2017-06-30 $0.07B $0.01B 8.93
2017-03-31 $0.08B $0.02B 4.94
2016-12-31 $0.09B $0.02B 6.15
2016-09-30 $0.05B $0.02B 3.23
2016-06-30 $0.05B $0.01B 3.29
2016-03-31 $0.06B $0.01B 4.07
2015-12-31 $0.07B $0.01B 4.88
2015-09-30 $0.07B $0.01B 5.89
2015-06-30 $0.08B $0.01B 7.21
2015-03-31 $0.04B $0.01B 6.67
2014-12-31 $0.05B $0.01B 10.91
2014-09-30 $0.05B $0.00B 11.66
2014-06-30 $0.04B $0.00B 11.08
2014-03-31 $0.05B $0.00B 11.09
2013-12-31 $0.06B $0.01B 11.88
2013-09-30 $0.02B $0.01B 2.04
2013-06-30 $0.00B 0.00
2013-03-31 $0.00B 0.00
2012-12-31 $0.00B 0.00
2012-09-30 $0.00B 0.00
2011-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $6.557B $0.031B
Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71